{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-103997","form_type":"8-K","ticker":"NMRA","cik":"0001885522","company_name":"Neumora Therapeutics, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.514017+00:00","generated_at":"2026-05-17T19:59:06.604898+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Neumora Q2 net loss $52.7M, cash $217.6M; advances NMRA-861 Phase 1, obesity lead for NMRA-215","bullets":["Cash, equivalents and marketable securities of $217.6M as of June 30, 2025; expected to fund operations into 2027.","Q2 net loss $52.7M vs $58.7M in Q2 2024; R&D expense fell to $38.7M from $48.6M.","Initiated Phase 1 SAD/MAD study of M4 PAM NMRA-861; data expected Q1 2026.","Prioritized obesity as lead indication for NLRP3 inhibitor NMRA-215; preclinical DIO data expected in 2025, clinical start Q1 2026.","Expects up to six clinical data readouts over next 18 months including navacaprant Phase 3 (1H 2026) and NMRA-511 Phase 1b (end 2025)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-103997","json":"https://secwatch.observer/filing/0000950170-25-103997.json","markdown":"https://secwatch.observer/filing/0000950170-25-103997.md","text":"https://secwatch.observer/filing/0000950170-25-103997.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025103997/0000950170-25-103997-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025103997/nmra-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:59:06.604898+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}